Chongqing expert consensus on biologics treatment for type 2 inflammatory asthma
The Development Group of Chongqing Expert Consensus on Biologics Treatment for Type 2 Inflammatory Asthma
Respiratory Physician Branch of Chongqing Medical Doctor Association
Respiratory Medicine Management Expert Committee of Chongqing Hospital Management Association
Chongqing Center of Prevention and Treatment for Chronic Respiratory Diseases
Chongqing Center of Medical Quality Control for Respiratory Diseases
GUO Shu-liang
Abstract：Severe asthma is a chronic inflammatory disease that seriously affects the life quality of patients.Type 2 inflammation phenotype accounts for a high proportion in patients with severe asthma in China.In the management of type 2 inflammatory asthma,the biologics therapy,as an emerging,targeted therapeutic strategy with significant efficacy,is becoming increasingly important.In response to the lack of experience in the use of biologics by the majority of respiratory physicians in China,the consensus,guided by the 13 clinical questions established through discussions at the expert group meeting,gives expert recommendations on the corresponding issues in terms of drug indications,drug selection,course of drug use,safety,drug combination,and efficacy prediction indicators,in order to help clinicians to improve their levels of decision-making in the use of biologics for asthma,thereby increasing standardized treatment level and control rate of type 2 inflammatory asthma.
Keywords：severe asthmatype 2 inflammatory asthmabiotherapybiologicsomalizumabbenralizumabmepolizumabreslizumabdupilumabtezepelumabexpert consensus
Publication Date：2025-06-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：11( 484-494 )